Healthcare / BiotechnologyParis
$0.02
-0.00 (-7.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-13.1M · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2M
P/E
N/A
•EV/EBITDA
N/A
•ROE
N/A
•Gross Margin
N/A
•Debt/Equity
-0.68
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income — · FCF $-8.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | — | — | $-17.0M | $-24.2M | $-31.2M |
| EBITDA | $-9.3M | $-9.3M | $-15.1M | $-22.8M | $-30.3M |
| EPS | -2.00 | -2.00 | -12.54 | -55.40 | -104.00 |
| Balance Sheet | |||||
| Debt/Equity | -0.68 | -0.68 | -1.58 | -2.32 | 2.23 |
| Current Ratio | 0.35 | 0.35 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-8.6M | $-8.6M | $-13.1M | $-19.1M | $-24.1M |
| Returns | |||||
| ROE | — | — | 441.4% | 1288.8% | -534.1% |
| Valuation | |||||
| P/B | — | — | — | — | 9.41 |
| Growth & Yield | |||||
| EPS Growth | 84.1% | 84.1% | 77.4% | 46.7% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-85.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-12.54 → -2.00
Residual
-85.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.